Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 23 Dec 2021 – 20 Aug 2026, limited by DSP Nifty Midcap 150 Quality 50 ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | DSP Nifty Midcap 150 Quality 50 ETF | Nifty Midcap 150 |
|---|---|---|
| 23 Dec 2021 | ₹100.00 | ₹100.00 |
| 14 May 2022 | ₹87.75 | ₹89.59 |
| 03 Oct 2022 | ₹95.81 | ₹101.68 |
| 21 Feb 2023 | ₹92.38 | ₹102.05 |
| 13 Jul 2023 | ₹101.58 | ₹119.22 |
| 02 Dec 2023 | ₹113.90 | ₹141.98 |
| 22 Apr 2024 | ₹120.91 | ₹160.76 |
| 10 Sep 2024 | ₹150.84 | ₹192.67 |
| 30 Jan 2025 | ₹133.81 | ₹172.04 |
| 21 Jun 2025 | ₹143.86 | ₹187.66 |
| 10 Nov 2025 | ₹143.24 | ₹195.07 |
| 31 Mar 2026 | ₹122.93 | ₹171.31 |
| 20 Aug 2026 | ₹147.36 | ₹206.20 |
| Metric | DSP NAV ₹25.57 Very High risk ★★☆☆☆ | Category median Other ETFs · 248 funds |
|---|---|---|
| +1.84% | +3.65% | |
| +11.51% | +10.51% | |
| — | +9.28% | |
| — | +11.93% | |
| +8.68% | +10.38% | |
| +10.12% | — | |
| +13.55% | +14.30% | |
| — | +13.74% | |
| — | +12.83% | |
| Risk | ||
| 15.41% | 15.45% | |
| 0.33 | 0.28 | |
| 0.45 | 0.41 | |
| -21.42% | -20.59% | |
| Nifty Midcap 150 | — | |
| -5.08% | +0.80% | |
| 0.92 | 1.00 | |
| 82.7% | 102.1% | |
| 101.5% | 96.4% | |
| 0.47% | 0.32% | |
| ₹96.73Cr | ₹137.31Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Anil Ghelani | — | |
| 23 Dec 2021 | — | |
| 50 | — | |
| 35.2% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.